Thomson Reuters and ChemAxon Partner to Help Speed Drug Discovery for Life Science Researchers
News Jan 05, 2011
The IP Solutions business of Thomson Reuters®, the leader in intellectual property research and analysis solutions, and ChemAxon, the leader in cheminformatics software for the life sciences industry, today announced a strategic partnership whereby Thomson Reuters is providing its chemical IP Data Feeds – Markush Structures and patent data to users of ChemAxon’s JChem chemical software platform. This search and analysis solution will speed drug discovery and allow life science researchers to easily integrate critical content into their existing systems and workflow.
The Markush structures from Thomson Reuters are part of the company’s Derwent World Patents Index® (DWPISM) database, the world’s most trusted and authoritative source of global patent information. The Markush database contains essential data on the relationship or “families” of 550,000 patents, making it the world’s leading source for life sciences patentability research, competitive intelligence and IP screening. ChemAxon’s JChem software allows life science professionals to structure and visualize chemical compounds for property prediction, virtual synthesis, screening and drug design. Through this partnership R&D end users can now research and analyze Markush structures using ChemAxon’s JChem chemical software platform, a means they had no access to before. The ability to quickly retrieve this information will now allow R&D end users to save time and capitalize on R&D investment.
“The ability to search and visualize complex chemical patents is critical to the work of life science R&D professionals. To date, however, this has been a challenge as there wasn’t a tool that enabled R&D end users to do this type of work themselves,” said Cindy Poulos, vice president of product management, Thomson Reuters. “Through this partnership, Thomson Reuters and ChemAxon are making a comprehensive worldwide database of chemical compounds widely accessible in a user-friendly, flexible format to end users.”
“The Markush structures database has become a vital backbone of pharmaceutical research in the digital age,” said Alex Drjver, CEO of ChemAxon. “By delivering this data directly to the end user in an intuitive, flexible format, our clients have access to the functionality and data necessary to stay competitive in today’s fast-paced, complex marketplace.”
The Thomson Reuters IP Data Feed - Markush Structures database is indexed from 550,000 patent families, plus 1.7 million related, exemplified, specific compounds. It includes patents for pharmaceuticals, agrochemicals and general chemistry spanning 26 patent-issuing authorities. Markush data is integrated with high-quality patent summary data from DWPI, enabling access to enhanced patent abstracts, family and assignee details, and relevant bibliographic data.
In malignant tumors, the cells usually proliferate quickly and uncontrollably. Researchers have discovered that two important regulators of cell division can interact in this process. If this is the case, affected patients have particularly poor chances of survival. The long-term goal is to suppress tumor growth by blocking the interaction.READ MORE